MiR-4429 Alleviates Malignant Behaviors of Lung Adenocarcioma Through Wnt/β-Catenin Pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Lung adenocarcinoma (ADC) is a prevalent non-small cell lung cancer subtype.
• MicroRNAs (miRNAs) are crucial biomarkers for cancer diagnosis and therapeutic targets.
• The specific role of miR-4429 in lung ADC progression remains largely unexplored.

Purpose of the Study:

• To investigate the expression and function of miR-4429 in lung ADC.
• To determine the molecular targets and signaling pathways regulated by miR-4429.
• To evaluate the therapeutic potential of miR-4429 in lung ADC.

Main Methods:

• Quantitative real-time PCR to assess miR-4429 expression in lung ADC cells.
• In vitro assays using miR-4429 mimics to evaluate effects on cell proliferation, migration, and epithelial-mesenchymal transition (EMT).
• Western blot analysis and luciferase reporter assays to confirm the binding of miR-4429 to beta-catenin and its regulatory effect on the Wnt/beta-catenin pathway.

Main Results:

• MiR-4429 expression was significantly downregulated in lung ADC cells.
• Overexpression of miR-4429 using mimics suppressed cell proliferation, metastasis, and reversed EMT.
• MiR-4429 directly targets beta-catenin, leading to its downregulation and inactivation of the Wnt/beta-catenin signaling pathway.
• The compound SKL2001 was found to reverse the tumor-suppressive effects of miR-4429.

Conclusions:

• MiR-4429 functions as a tumor suppressor in lung ADC.
• Targeting beta-catenin and inactivating the Wnt/beta-catenin pathway are key mechanisms by which miR-4429 inhibits lung ADC progression.
• MiR-4429 holds potential as a therapeutic agent for lung ADC, although further investigation into modulators like SKL2001 is warranted.